| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Quoin Pharmaceuticals, Ltd.$4.45
-0.22 (-4.71%)
D 27Pipeline Score Richly Valued Pharma · Clinical
Market Cap
9.35 M
EPS
-236.73
P/E Ratio
-
Value Trade
190.00 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.43 M
Operating CF
-4.87 M
Total Assets
15.69 M
Total Liabilities
6.92 M
Equity
8.77 M
D/E Ratio
12,345
-17.04 %
Week
-19.7 %
1 Month
-47.52 %
3 Month
-74.89 %
6 Month
-99.99 %
5 Year
-100 %
All Time
Cash Data
Cash Position
14.04 M
Monthly Burn
1.62 M
Runway
6.8 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
24.77 K
52 Week Range
4.59 - 41.80
% held by Insiders
-
% held by Institutions
67.31 %
Enterprise Value
-4.69 M
Total Shares
1.96 M
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Quoin Pharmaceuticals, Ltd.
433Total events
8Upcoming
106Tier-1 (high impact)
2016 – 2028Coverage
Upcoming catalysts 8
Event history 425
Jul 9, 2026
▲IND ClearanceQRX003, 4%IND
FDA IND clearance for QRX003 in Peeling Skin Syndrome
Peeling Skin Syndromesource ↗
Q3 2026
◆Trial InitiationQRX003, 4%Trial
Initiate pivotal Phase 3 study of QRX003 in Netherton Syndrome
Netherton Syndromesource ↗
Q3 2026
Q3 2026
●IND SubmissionQRX009IND
Submit IND to FDA for QRX009 for an additional indication
additional indication (not specified)source ↗
Q3 2026
◆Topline ReadoutQRX003, 4%Clinical Data
Top-line data anticipated from two pivotal trials
Netherton Syndromesource ↗
Jun 30, 2026
▲Patent GrantedQRX003, 4%IP / Competition
USPTO issued Notice of Allowance for patent covering combination treatment for Netherton Syndrome
Netherton Syndromesource ↗
Jun 23, 2026
▲FDA Feedback ReceivedQRX003, 4%FDA Meeting
FDA conditional approval of QYLEKI as proposed brand name for QRX003
Netherton Syndromesource ↗
Jun 18, 2026
▲Other Regulator MilestoneQRX003, 4%Ex-US Regulatory
Establishment of Japanese subsidiary for commercial readiness
Netherton Syndromesource ↗
Jun 18, 2026
▲Orphan Drug DesignationQRX003, 4%Designation
Orphan Drug Designation granted by Japan's MHLW
Netherton Syndromesource ↗
Jun 16, 2026
▲Enrollment UpdateQRX003, 4%Trial
Six pediatric patients enrolled in compassionate use program
Netherton Syndromesource ↗
Jun 16, 2026
▲Topline ReadoutQRX003, 4%Clinical Data
Positive clinical update: 4 of 6 patients improved or significantly improved
Netherton Syndromesource ↗
Jun 15, 2026
▲Enrollment UpdateQRX003, 4%Trial
Additional pediatric patient enrolled on June 15, 2026
Netherton Syndromesource ↗
Drug Pipeline Intelligence
D27
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 29%
Micro Cap (rank 648 of 911)
Percentile RankQuoin Pharmaceuticals, Ltd. faces pipeline headwinds (27/100), with 2 assets in development.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QRX003-2% Small molecule | Netherton Syndrome | Phase 2 | NCT05521438 | 52% | $3M | ACTIVE NOT_RECRUITING | 30 | SLOW | C (52) | Dec 31, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
QRX003 Fast TrackOrphanRare Pediatric | Netherton Syndrome | — | 2025-10-28 | IGA baseline: 4; IGA 9 months: 0; pruritus baseline: 5; pruritus 9 months: 0 Read More | Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study Read More | |
QRX003 Fast TrackOrphanRare Pediatric | Netherton Syndrome | — | 2025-10-28 | IGA baseline: 4; IGA 9 months: 0; pruritus baseline: 5; pruritus 9 months: 0 Read More | Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study Read More | |
QRX003 Fast TrackOrphanRare Pediatric | Netherton Syndrome | — | 2025-10-28 | IGA baseline: 4; IGA 9 months: 0; pruritus baseline: 5; pruritus 9 months: 0 Read More | Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QNRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QNRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QNRX▼ -4.7%today
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals has received FDA IND clearance to initiate a Phase 2 study of QRX003 for Peeling Skin Syndrome, expected to start in the second half of 2026. This marks the first formal clinical study for this condition, which currently has no approved treatments. The study aims to enroll 6-8 patients in the U.S. and Europe, with a focus on developing a much-needed therapy.
Read more →QNRX▲ +6.4%on this news
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
Quoin Pharmaceuticals has received a Notice of Allowance from the USPTO for a patent covering a combination treatment for Netherton Syndrome. This patent supports their investigational drug QRX003, which could become the first approved treatment for this rare genetic skin disease. The allowed claims include treatment methods for patients with SPINK5 mutations, enhancing Quoin's intellectual property position.
Read more →QNRX▼ -26.3%on this news
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
Quoin Pharmaceuticals has received conditional FDA approval for the brand name QYLEKI for QRX003, its investigational treatment for Netherton Syndrome. This marks a significant milestone as the company prepares for a pivotal Phase 3 study expected to start in late 2026, with a potential NDA filing in 2027. QRX003 has received Orphan Drug and Fast Track designations, indicating strong regulatory support.
Read more →QNRXQuoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Quoin Pharmaceuticals has established a wholly-owned subsidiary in Japan to facilitate the direct commercialization of QRX003, aimed at treating Netherton Syndrome. This move follows the recent Orphan Drug Designation granted by Japan's MHLW. Quoin's strategy includes building commercial infrastructure in Japan, which is one of its three core markets, alongside the U.S. and Western Europe.
Read more →QNRXQuoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Quoin Pharmaceuticals has provided a positive clinical update on its Compassionate Use program for pediatric Netherton Syndrome, with four out of six patients showing improvements across key clinical endpoints. The youngest participant, only 6 months old, saw significant benefits after just three weeks of treatment. No adverse events related to the treatment were reported, emphasizing the safety of their product, QRX003. Quoin aims to enroll additional patients and will release comprehensive data from the program in the coming months.
Read more →QNRXQuoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome -Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclus
Quoin Pharmaceuticals has announced that Japan's MHLW has granted Orphan Drug Designation for QRX003, aimed at treating Netherton Syndrome. This designation offers significant regulatory incentives, including market exclusivity upon approval. Quoin has already received similar recognitions from the U.S. FDA and the European Medicines Agency. The company is currently fine-tuning its clinical and regulatory paths in collaboration with Japanese clinicians, aiming to start pivotal Phase 3 trials later in 2026.
Read more →QNRXQuoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals has submitted an IND application for QRX003 to treat Peeling Skin Syndrome, marking a significant milestone as it is the first submission for this disease. The application is backed by positive results from an ongoing pediatric study. Quoin plans to initiate a Phase 2 clinical study in the second half of 2026, recruiting patients in the US and Europe.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results - Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome - Submitted Applicati
Quoin Pharmaceuticals announced significant progress in its regulatory activities regarding QRX003 for Netherton Syndrome. The company filed for Breakthrough Medicine Designation with the Saudi FDA and received Fast Track Designation from the U.S. FDA, with indications that a single Phase 3 study may be sufficient for marketing approval. Quoin is also on track for an NDA filing in 2027. Furthermore, the company saw an increase in net loss for Q1 2026 compared to the same period in the previous year, highlighting potential financial challenges.
Read more →QNRX▲ +9.3%on this news
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
Quoin Pharmaceuticals Ltd. plans to announce a corporate update and its financial results for Q1 2026 on May 7, 2026. The announcement will include operational highlights and financial achievements. Quoin specializes in developing therapies for rare diseases, with a focus on two main products, QRX003 and QRX009.
Read more →QNRXCORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Quoin Pharmaceuticals announced a clinical and regulatory update for its QRX009 topical rapamycin programs. The company plans to initiate several investigator-led studies, starting with Pachyonychia Congenita, led by Professor Edel O'Toole. Additionally, Quoin aims to submit an Investigational New Drug Application to the FDA for QRX009 by Q3 2026, targeting multiple indications.
Read more →QNRXQuoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Quoin Pharmaceuticals announced an update on its development programs for QRX009, a topical rapamycin designed for rare skin diseases. The company plans to initiate several investigator-led clinical studies targeting Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex. Notably, the study on Pachyonychia Congenita will be led by renowned expert Professor Edel O'Toole. Additionally, Quoin aims to submit an Investigational New Drug Application to the FDA for QRX009 for another indication, with multiple studies expected to commence by the end of 2026.
Read more →QNRX▼ -18.4%on this news· ran to -31% by day 1
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Quoin Pharmaceuticals reported significant advancements in its corporate update for Q4 and full-year 2025. The company secured Orphan Drug Designations for QRX003 for Netherton Syndrome in both the U.S. and Europe and closed a private placement financing of up to $104.5 million. Clinical studies for QRX003 show promising long-term efficacy and safety, with plans for further expansion and regulatory submissions in 2026.
Read more →QNRX▲ +15.9%on this newsshared move
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals provided an update following a Type C meeting with the FDA regarding QRX003 for Netherton Syndrome. The FDA indicated that a single Phase 3 study may be sufficient for marketing approval, which is a shift from the previously expected two studies. Quoin plans to initiate the Phase 3 study and complete patient recruitment by 2026, aiming for NDA submission in 2027.
Read more →QNRX▲ +5.4%on this news
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
Quoin Pharmaceuticals Ltd. has announced plans to provide a corporate update and financial results for the fourth quarter and full year of 2025 on March 26, 2026. This update will include highlights of key achievements and financial performance for the year. Quoin, specializing in rare and orphan diseases, aims to inform stakeholders about its operational progress and product pipeline developments.
Read more →QNRXQuoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome - Fast Track Designation facilitates development and expedites regulatory review of therapies addressin
Quoin Pharmaceuticals has announced that the FDA has granted Fast Track Designation for its QRX003 lotion, aimed at treating Netherton Syndrome. This designation is expected to expedite the development and review process due to the severe nature of this rare genetic skin disorder that currently lacks approved therapies. QRX003 is currently undergoing late-stage clinical trials to establish its safety and efficacy. The positive FDA decision follows prior designations for the product, highlighting its importance in addressing a significant unmet medical need for patients.
Read more →QNRXNETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
Quoin Pharmaceuticals Ltd. has recognized Rare Disease Day 2026 by highlighting its NETHERTON NOW awareness campaign for Netherton Syndrome, a rare genetic disorder. The campaign aims to amplify the voices of affected patients and caregivers, achieving nearly 2 million video views and over 24 million impressions globally. The company emphasizes the need for action alongside awareness, as it continues to develop its investigational candidate QRX003 for treatment.
Read more →QNRXQuoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals has submitted an application for Orphan Drug Designation for QRX003 to the Japanese MHLW, which confirmed its eligibility for both ODD and Fast Track review. If approved, QRX003 will have orphan status in the US, EU, and Japan. The company is also setting up a subsidiary in Japan to facilitate commercialization efforts.
Read more →QNRXQuoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals has filed for Breakthrough Medicine Designation for QRX003 with the Saudi Food and Drug Authority, aiming to expedite its approval as a treatment for Netherton Syndrome. If granted, QRX003 could be available as early as the second half of 2026, marking a significant milestone for both the company and patients. The product has already received various designations from regulatory bodies in the U.S. and Europe.
Read more →QNRX▲ +41.4%on this news· ran to +85% by day 3
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies
Quoin Pharmaceuticals has achieved target rapamycin loadings of 4% and 5% for its topical lotion and dermal patch delivery systems. The company plans to manufacture clinical trial batches in Q4 2025 and commence clinical testing in early 2026 for conditions such as Microcystic Lymphatic Malformations and Venous Malformations. This milestone is seen as a significant step forward in their clinical development pipeline.
Read more →QNRX▼ -11.2%on this newsshared move
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results
Quoin Pharmaceuticals announced a corporate update and financial results for Q3 2025, highlighting a successful $105.3 million private placement financing and the FDA's orphan drug designation for QRX003 targeting Netherton Syndrome. The company is set to commence pivotal studies for QRX003 in Q4 2025, supported by positive clinical data and an expanding awareness campaign. However, they reported an increased net loss due to rising research and development costs.
Read more →QNRX▼ -7.2%on this news· ran to -20% by day 3
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Quoin Pharmaceuticals Ltd. plans to provide a corporate update and announce its financial results for Q3 2025 on November 6, 2025. The update will cover key operational achievements, recent accomplishments, and financial highlights from the quarter ending on September 30, 2025. As a late clinical-stage specialty pharmaceutical company, Quoin is dedicated to developing therapies for rare and orphan diseases.
Read more →QNRXQuoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study
Quoin Pharmaceuticals has announced the recruitment of three additional patients in its pediatric Netherton Syndrome study and reported positive nine-month clinical data from the first patient. The patient experienced complete skin healing and elimination of pruritus, marking a significant improvement. The ongoing study aims to gather more data to support QRX003 as a treatment for this rare condition.
Read more →QNRXQuoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals has received Orphan Drug Designation from the FDA for QRX003, aimed at treating Netherton Syndrome. This designation follows a similar recognition from the EMA earlier in 2025. QRX003 is currently in late-stage clinical trials, with plans for NDA submission later in 2026. If approved, it will offer seven years of market exclusivity in the U.S.
Read more →QNRX▲ +151.2%on this news
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million
Quoin Pharmaceuticals has announced a private placement financing agreement that could raise up to $104.5 million. The deal includes an initial $16.5 million and potential additional funds through warrants. The financing aims to support the company's ongoing clinical development of treatments for rare diseases, including Netherton Syndrome. The private placement is expected to close around October 14, 2025.
Read more →QNRXQuoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome
Quoin Pharmaceuticals has released the fifth episode of its NETHERTON NOW video series, featuring twin sisters Allie and Kaleigh Fasanella, who share their experiences living with Netherton Syndrome. They discuss the emotional and physical toll of the disease, emphasizing the importance of awareness and support. The episode highlights Quoin's commitment to developing QRX003, a potential treatment currently in clinical trials.
Read more →QNRXQuoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome
Quoin Pharmaceuticals' NETHERTON NOW campaign has achieved over one million video views, significantly raising awareness about Netherton Syndrome. The initiative highlights personal stories and clinical insights, aiming to improve understanding of this rare genetic condition. Quoin's investigational drug, QRX003, is in late-stage trials, with full enrollment expected by early 2026.
Read more →QNRXQuoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
Quoin Pharmaceuticals has appointed Sally Lawlor as its new Chief Financial Officer to enhance its commercialization strategy. With over 20 years of experience, Lawlor will guide the company as it advances its lead product, QRX003, through pivotal clinical trials for Netherton Syndrome. The company is also preparing for a potential NDA filing next year.
Read more →QNRXQuoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton
Quoin Pharmaceuticals has released the fourth episode of its NETHERTON NOW video series, featuring patient advocate Mandy Aldwin-Easton. In the video, she discusses her struggles with Netherton Syndrome and the urgent need for better treatments. Quoin continues to advance its lead product candidate, QRX003, in pivotal trials aimed at addressing the significant unmet needs of patients with this rare disease.
Read more →QNRX▼ -6.2%on this newsshared move
Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update - Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study - FDA Clears Second Pivotal Study of QRX
Quoin Pharmaceuticals reported their second quarter financial results for 2025, highlighting significant advancements in their clinical studies, particularly regarding QRX003 for Netherton Syndrome. The ongoing pediatric study demonstrated positive and durable clinical improvements after six months of treatment. Furthermore, the FDA granted Rare Pediatric Disease Designation and the European Medicines Agency provided Orphan Drug Designation for QRX003, which could expedite its development process. The company emphasized their commitment to raising awareness for treatment options through their advocacy initiatives.
Read more →QNRX▼ -12.4%on this news
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Quoin Pharmaceuticals has announced the release date for its second quarter 2025 financial results, which will be disclosed on August 7, 2025. The report is expected to include an operational update detailing key achievements and financial highlights for the quarter ending June 30, 2025. The company specializes in developing treatments for rare and orphan diseases, with a focus on unmet medical needs.
Read more →QNRXQuoin Pharmaceuticals Provides Product Portfolio Update
Quoin Pharmaceuticals has provided an overview of its product portfolio, focusing on the lead product QRX003 for Netherton Syndrome, currently in two pivotal registrational clinical studies across multiple regions. Positive initial data for QRX003 was also reported in a clinical study for Peeling Skin Syndrome, prompting plans for further recruitment. Additionally, advancements in topical rapamycin development targeting rare skin diseases are highlighted. However, the company has ceased development on certain products to prioritize their resources.
Read more →QNRXQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
Quoin Pharmaceuticals has launched a new episode in its NETHERTON NOW video series, featuring Professor Jemima Mellerio discussing Netherton Syndrome, a severe genetic skin disorder. The video emphasizes the challenges faced by affected infants and young children and highlights the critical need for targeted treatments. Notably, Quoin's lead product candidate, QRX003, has received Rare Pediatric Disease Designation from the FDA, underlining the urgency for better therapeutic options. Overall, this initiative aims to educate the public and elevate the voices of those impacted by the condition.
Read more →QNRXQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals announced that the FDA has granted Rare Pediatric Disease Designation for its lead asset QRX003, aimed at treating Netherton Syndrome, a severe genetic disorder. This designation reflects the potential of QRX003 for a largely underserved pediatric population, coming shortly after the EMA's Orphan Drug Designation. The company aims to advance QRX003 towards a New Drug Application, supported by promising clinical data. If approved, Quoin could benefit from a Priority Review Voucher, expediting future marketing applications.
Read more →QNRXQuoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label sy
Quoin Pharmaceuticals has received FDA clearance to initiate its second pivotal clinical study, CL-QRX003-002, for its lead product QRX003, targeting Netherton Syndrome. This study seeks to evaluate the whole-body application of QRX003 in conjunction with off-label systemic therapies. Historical data shows that QRX003 has the potential to significantly heal skin and alleviate associated symptoms. The company plans to enroll 24-30 subjects across U.S. and international sites, aiming to complete recruitment by the end of Q1 2026 and file for NDA later in the year.
Read more →QNRX▲ +6%on this newsshared move
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome Company continues to advance QRX003 in late-stage clinical trials in Nethe
Quoin Pharmaceuticals has been granted Orphan Drug Designation by the European Medicines Agency for its investigational product QRX003, aimed at treating Netherton Syndrome. This designation provides incentives such as scientific advice, fee reductions, and access to EU grants, ensuring market exclusivity for 10 years upon product approval. The CEO highlighted encouraging efficacy signals and a favorable safety profile from ongoing late-stage clinical trials, reinforcing QRX003's potential as a significant therapeutic option for this rare condition, which currently lacks approved treatments.
Read more →QNRX▲ +20.3%on this news
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
Quoin Pharmaceuticals has announced initial positive clinical data from its study on QRX003 for Pediatric Peeling Skin Syndrome. After 12 weeks of treatment, significant improvements were observed in the patient's skin appearance across key clinical endpoints. The treatment was well tolerated, with no adverse events reported. The company aims to further assess the patient's progress and potentially expand the study to include more pediatric subjects.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
Quoin Pharmaceuticals has reported positive developments in its late-stage studies for Netherton Syndrome, particularly regarding its treatment QRX003. The company announced compelling clinical data showing significant skin healing and relief from symptoms in both adult and pediatric patients. Additionally, Quoin has expanded its patent portfolio to support new formulations for rare skin diseases. Alongside these advancements, the NETHERTON NOW advocacy initiative was launched to further raise awareness and support for the Netherton community.
Read more →QNRXQuoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Quoin Pharmaceuticals Ltd. has announced that it will release its financial results for the first quarter of 2025 on May 13, 2025. This report will provide an operational update, including key achievements and financial highlights of the company. Quoin Pharmaceuticals specializes in developing treatments for rare and orphan diseases and has four products in its pipeline aimed at addressing significant medical needs.
Read more →QNRXQuoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Quoin Pharmaceuticals Ltd. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. This comes after the company's ordinary shares maintained a closing bid price at or above $1.00 for 13 consecutive business days. Nasdaq has deemed the compliance issue resolved, marking a positive development for the company's stock status. Quoin continues to focus on developing treatments for rare and orphan diseases with a promising pipeline.
Read more →QNRX▼ -20.3%on this news
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
Quoin Pharmaceuticals has released the second episode of its 'Living with Netherton' video series, part of the NETHERTON NOW awareness campaign. This episode features Norma Coles, a 79-year-old patient with a long history of Netherton Syndrome. The campaign aims to raise awareness and support for individuals affected by this rare condition, highlighting the challenges they face, including misdiagnosis and treatment gaps. Quoin continues to develop QRX003, a potential treatment for the syndrome, with ongoing clinical trials showing promising results.
Read more →QNRX▲ +38.2%on this news
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
Quoin Pharmaceuticals announced highly positive results from their ongoing clinical study of QRX003 for Netherton Syndrome. After 6 weeks of treatment, a pediatric patient showed almost complete skin healing and has not required other medications. Additionally, the patient reported no sleep disturbances, indicating significant improvement in quality of life. Quoin has also received approval to initiate testing on a second pediatric patient, furthering their research in this area.
Read more →QNRXQuoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for novel topical formulations aimed at treating Netherton Syndrome and other skin diseases. The company is currently conducting multiple clinical trials for its lead product, QRX003, which has shown positive initial data. If granted, the patent would provide coverage for QRX003 until 2045. Quoin remains the only company actively testing treatments for Netherton Syndrome under an open IND, reflecting its commitment to addressing unmet medical needs in rare diseases.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results ASHBURN, Va.
Quoin Pharmaceuticals recently announced a corporate update alongside its fourth quarter and full-year 2024 financial results. The company highlighted significant progress in its clinical developments, particularly with QRX003 for Netherton Syndrome, showing positive data from ongoing studies. Quoin also secured FDA clearance for a new clinical study to evaluate QRX003 across a larger body surface area. Further expansion of their pipeline is evidenced by recent patent filings for novel topical formulations aimed at treating additional rare diseases.
Read more →QNRX▼ -7.3%on this news
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
Quoin Pharmaceuticals Ltd. has announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024, on March 13, 2025. The announcement will provide an operational update that highlights key achievements, recent accomplishments, and financial results for 2024. Quoin specializes in developing therapeutic products targeting rare and orphan diseases, aiming to meet significant medical needs in this area.
Read more →QNRXQuoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
Quoin Pharmaceuticals Ltd. has filed U.S. and international patent applications for novel topical rapamycin formulations aimed at treating rare diseases, including microcystic lymphatic malformations and venous malformations. The products utilize the company’s proprietary Invisicare delivery technology designed to enhance the drug's local skin penetration. Quoin plans to submit Investigational New Drug Applications and commence clinical testing within the year. Currently, there are no FDA-approved treatments for the targeted indications, and previous formulations of rapamycin have not met clinical expectations.
Read more →QNRX▲ +15.4%on this newsshared move
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Quoin Pharmaceuticals announced positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome study, showing significant improvement in one patient after two weeks of whole-body treatment with QRX003. The patient experienced marked skin healing, a decrease in pruritus, and discontinued various medications including antihistamines and glucocorticoids. Importantly, the treatment resulted in the patient experiencing no nightly sleep disturbances. The results suggest a promising potential for QRX003 in treating Netherton Syndrome, although the company cautions that these findings are based on a single patient case.
Read more →QNRXQuoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome
Quoin Pharmaceuticals announced the launch of 'Living with Netherton,' a video series aimed at raising awareness for Netherton Syndrome, a severe genetic disorder. The series starts on Rare Disease Day, February 28, 2025, featuring personal stories from families affected by this condition. The campaign aims to educate the public about the challenges faced by patients and push for greater advocacy. Quoin's lead candidate, QRX003, is currently under clinical evaluation as a potential treatment for Netherton Syndrome, highlighting the company's dedication to developing therapeutics for rare diseases.
Read more →QNRXQuoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure
Quoin Pharmaceuticals has launched the 'NETHERTON NOW' campaign to increase awareness of Netherton Syndrome, a rare genetic condition with no current approved treatment. The campaign includes an interactive website and emphasizes the urgent need for better understanding and advocacy for patients suffering from this debilitating disorder. Quoin is progressing towards obtaining regulatory approval for its treatment, QRX003, which has demonstrated positive clinical data. The campaign aims to provide support and resources for patients and families impacted by the disease.
Read more →QNRX▼ -30.2%on this news· ran to -46% by day 3
Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
Quoin Pharmaceuticals announced positive clinical evidence supporting the effectiveness of QRX003 in treating Netherton Syndrome following a recent open-label study. Data revealed that all clinical improvements observed during treatment were completely reversed four weeks after discontinuation, suggesting a need for ongoing treatment. The company aims to expedite the development of QRX003, which could be the first approved treatment for this rare skin disorder, while maintaining commitment to broadening their clinical data package.
Read more →QNRXQuoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Quoin Pharmaceuticals has announced positive interim results from its ongoing clinical study of QRX003 for pediatric Netherton Syndrome. The study shows that subjects' skin conditions improved from 'Severe' to 'Mild' after six weeks of treatment. Due to these promising results, the treatment area has been expanded to cover the whole body. Importantly, there have been no reported adverse events, further supporting the safety of QRX003.
Read more →QNRXQuoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
Quoin Pharmaceuticals has announced additional positive interim data from its ongoing clinical study of QRX003 for Netherton Syndrome. The latest findings demonstrate significant clinical benefits, with marked improvements observed across all measured endpoints for the first subject dosed twice daily. Notably, patient satisfaction scores have continued to rise, and no safety concerns were identified throughout the study. The company plans to initiate a whole body clinical study, aiming to support a New Drug Application for QRX003 as a potential first treatment for this rare condition.
Read more →QNRX▼ -12%on this news
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering ASHBURN, Va.
Quoin Pharmaceuticals has announced the pricing of a public offering valued at $6.8 million, involving the provision of 15,111,110 ordinary shares alongside Series F and G warrants. The offering is set to close around December 23, 2024, pending typical closing conditions. The company plans to allocate the proceeds for corporate purposes, including research and development, operational expenses, and general capital expenditures. Additionally, modifications have been made to existing warrants held by certain investors, adjusting exercise prices and expiration dates.
Read more →QNRX▲ +15%on this newsshared move
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
Quoin Pharmaceuticals has received FDA clearance to initiate a new clinical study for QRX003, a topical treatment for Netherton Syndrome. This groundbreaking study, led by Dr. Amy Paller at Northwestern University, will enroll up to eight subjects applying QRX003 to over 80% of their body surface area for 12 weeks. This approach aims to produce data more reflective of actual use by potential patients. The findings will complement existing data to support regulatory approval for QRX003, Quoin's commitment to developing a treatment for this rare condition.
Read more →QNRX▼ -6.7%on this newsshared move
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
Quoin Pharmaceuticals has announced positive interim clinical data from two studies concerning its treatment QRX003 for Netherton Syndrome. In the open label study, a subject exhibited significant clinical improvement after six weeks, with reductions in both the Modified Ichthyosis Area of Severity Index and pruritus severity. Additionally, children in the pediatric study showed improvement in skin condition as early as 12 days into treatment. The company expressed cautious optimism while noting the preliminary nature of these results.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Cl
Quoin Pharmaceuticals has provided a corporate update, highlighting key achievements in their ongoing development programs. The company is set to initiate a clinical study for QRX003 to treat Peeling Skin Syndrome, marking a significant step in addressing an unmet medical need. Additionally, Quoin is expanding its Netherton Syndrome clinical program by opening new sites in the UK. The management team has demonstrated their belief in the company’s potential with significant insider share purchases. Overall, Quoin aims to enhance its international reach and continue its commitment to rare disease therapies.
Read more →QNRXQuoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
Quoin Pharmaceuticals has initiated clinical testing of its lead product QRX003 in a pediatric patient with Netherton Syndrome at Children's Health Ireland in Dublin. This marks the first evaluation of QRX003 in children for this rare genetic disorder, for which there are no approved treatments. The testing is being overseen by Dr. Alan Irvine, a prominent dermatologist, and plans are in place to open a second clinical site in Spain, potentially increasing the cohort of pediatric patients involved. Initial results have been favorable, with no recorded adverse events, showing promise for the continued development of QRX003.
Read more →QNRX▼ -7.8%on this newsshared move
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Quoin Pharmaceuticals Ltd. has announced that it will release its third quarter 2024 financial results on November 7, 2024. The announcement is set to occur before the market opens and will include an operational update detailing the company’s achievements and financial highlights during the quarter. Quoin is focused on developing therapeutic products aimed at rare and orphan diseases, with a promising pipeline that targets several conditions.
Read more →QNRX▼ -13%on this news
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Quoin Pharmaceuticals has announced the expansion of its clinical trials for Netherton Syndrome to include two additional sites in the UK, specifically Great Ormond Street Hospital and St. Thomas' Hospital. Both sites are recognized centers of excellence for treating Netherton Syndrome, which supports the enrollment of eligible patients. The company is also preparing to open more sites in Western Europe and concluding a feasibility study in Eastern European countries. This expansion is part of Quoin's efforts to develop QRX003, a topical lotion aimed at treating this rare genetic disorder.
Read more →QNRX▲ +24.7%on this news
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
Quoin Pharmaceuticals has announced that its CEO Michael Myers and COO Denise Carter made significant insider purchases of the company's American Depositary Shares (ADSs) on September 3 and 4, 2024. These purchases are interpreted as a sign of confidence in the company's strategic direction and growth potential. Quoin Pharmaceuticals remains dedicated to developing treatments for rare and orphan diseases, with a promising pipeline of products. The company emphasizes its commitment to meeting unmet medical needs in underserved patient populations globally.
Read more →QNRX▼ -7.2%on this news
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-goi
Quoin Pharmaceuticals announced its second quarter 2024 financial results and provided a corporate update, highlighting a research partnership with University College Cork to develop topical rapamycin formulations. The company plans to expand clinical trials for its lead product QRX003 for Netherton Syndrome to international sites, starting in Saudi Arabia. Additionally, Quoin aims to initiate a clinical study for Peeling Skin Syndrome, a rare genetic condition, and continues evaluating M&A opportunities in the rare disease sector.
Read more →QNRXQuoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
Quoin Pharmaceuticals announced the initiation of a clinical study for QRX003, targeting Peeling Skin Syndrome (PSS), in New Zealand. This marks the second indication for QRX003, which is already under evaluation for Netherton Syndrome in the U.S. The study aims to assess the safety and efficacy of QRX003, addressing a critical need for effective treatments in this rare disease with no current approved options. The company is also exploring additional clinical sites in other countries as part of its broader strategy to expand its clinical testing efforts.
Read more →QNRXQuoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has announced it will release its financial results for the second quarter of 2024 on August 8, before market opening. The announcement is expected to provide an operational update and detail financial highlights. Quoin is focused on developing therapies for several rare and orphan diseases and has a pipeline of products under development. The company emphasizes its commitment to addressing significant unmet medical needs.
Read more →QNRXQuoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Quoin Pharmaceuticals has announced an expansion of its ongoing clinical trials for Netherton Syndrome to include international sites, starting with a location in Saudi Arabia. This site is already treating eligible patients and aims to enhance recruitment and patient diversity for the studies. The company is optimistic about its efforts and is committed to potentially delivering the first approved treatment for this underserved condition. Plans are in place to open additional international sites to complement existing ones in the U.S.
Read more →QNRXQuoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
Quoin Pharmaceuticals has announced its participation as a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference, which will take place from June 28-30, 2024, in Albuquerque, New Mexico. The conference aims to connect individuals impacted by ichthyosis and related skin conditions with medical experts and support networks. Quoin's COO expressed pride in supporting those affected by rare diseases and highlighted the company's dedication to developing treatments, particularly for Netherton Syndrome. Additionally, Quoin will sponsor a celebration dinner during the event.
Read more →QNRXQuoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
Quoin Pharmaceuticals has signed a research agreement with University College Cork (UCC) to develop novel topical formulations of rapamycin aimed at treating rare and orphan diseases. The collaboration will leverage UCC's proprietary microneedle technology to improve the drug's delivery and therapeutic effectiveness. Quoin plans to fund the research program and has the option to advance the clinical development of successful formulations. The agreement does not involve any upfront costs or royalties on future sales, potentially reducing financial risk.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
Quoin Pharmaceuticals has announced a corporate update detailing first quarter 2024 financial results and advancements in its clinical studies for Netherton Syndrome. The FDA has cleared the recruitment of teen subjects for ongoing trials, and the company has successfully expanded its intellectual property portfolio with a new patent application. Financially, Quoin reported approximately $14.7 million in cash and a reduced net loss of $2.3 million compared to the previous year. Additionally, the company has extended its cash runway into late 2025, allowing for the potential achievement of significant future milestones.
Read more →QNRXQuoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
Quoin Pharmaceuticals Ltd. has announced that it will release its first quarter 2024 financial results on May 9, 2024, prior to market opening. This announcement is expected to include key operational updates and financial highlights from the quarter. The company focuses on developing therapeutics for rare and orphan diseases, emphasizing its commitment to address unmet medical needs.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label N
Quoin Pharmaceuticals announced a corporate update alongside its fourth quarter and full year 2023 financial results. The company reported positive initial clinical data for its drug QRX003, aimed at treating Netherton Syndrome, and has lowered the eligibility age for its clinical studies to 14 years and older. Quoin's financial position has been strengthened with a recent $6.5 million capital raise and an $8 million equity line of credit is anticipated upon shareholder approval. Despite a substantial net loss and accumulated deficit, Quoin remains optimistic about advancing its treatment options for the rare disease community.
Read more →QNRX▼ -8.5%on this news
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
Quoin Pharmaceuticals will announce its fourth quarter and 2023 financial results on March 13, 2024, and will host a conference call the next day at 8:30 AM ET. The call will provide insights into the company's financial performance and updates on its corporate strategy. Quoin specializes in developing therapeutic products for rare and orphan diseases, aiming to address critical unmet medical needs in this field.
Read more →QNRX▼ -48.3%on this news· ran to -59% by day 3shared move
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
Quoin Pharmaceuticals Ltd. has announced the pricing of a public offering aimed at raising approximately $6.5 million through the sale of ordinary shares and associated warrants. The company intends to utilize the net proceeds for general corporate purposes. Additionally, Quoin has agreed to lower the exercise price of outstanding warrants from previous public offerings to align with the current offering. The closure of this offering is anticipated to occur shortly, pending customary conditions.
Read more →QNRXQuoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies Clearance to include teen patients in both the company's open label and placebo controlled stud
Quoin Pharmaceuticals has received FDA clearance to recruit teenagers aged 14 and older for its ongoing clinical trials of QRX003, aimed at treating Netherton Syndrome. This decision is a significant milestone as it marks the first inclusion of non-adult patients in Netherton Syndrome clinical studies under an open IND. The inclusion is expected to increase eligible participants, potentially accelerating recruitment and enhancing the robustness of the clinical data collected. The company remains dedicated to addressing the needs of the Netherton community and striving towards regulatory approval for QRX003.
Read more →QNRXQuoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
Quoin Pharmaceuticals Ltd. has announced the filing of U.S. and International patent applications for a novel combination product aimed at treating Netherton Syndrome. This innovative product incorporates a broad-spectrum serine protease inhibitor and an anti-inflammatory agent in a topical formulation. The company is currently conducting clinical trials for its QRX003 topical lotion, with an existing position as the only company recruiting for Netherton Syndrome under an open IND. The patents for this new product are expected to extend until at least 2044.
Read more →QNRX▼ -5.6%on this news
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials
Quoin Pharmaceuticals has received FDA clearance to optimize clinical trials for QRX003, aimed at treating Netherton Syndrome. Due to positive initial data and a strong safety profile, the company has increased trial sizes and adjusted dosing frequencies. The changes are expected to yield a more comprehensive data set, potentially accelerating the treatment's approval as the first effective therapy for this rare condition. Quoin emphasizes its commitment to developing solutions for underserved patients in this area.
Read more →QNRXQuoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
Quoin Pharmaceuticals has announced FDA clearance for a clinical optimization plan for its treatment QRX003, aimed at Netherton Syndrome. The company has seen positive initial data from ongoing trials, leading to a significant increase in the trial size and changes in the dosing schedule. These amendments aim to enhance the data obtained from these trials, with expectations that they will support future regulatory filings.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Synd
Quoin Pharmaceuticals has announced a corporate update alongside its financial results for Q3 2023. The company reported positive clinical data for its investigational treatment QRX003 in Netherton Syndrome, with notable improvements in several clinical endpoints. CEO Dr. Michael Myers expressed optimism about the data, specifically regarding pruritus relief in subjects. Despite this positive news, the company continues to face operating losses as it develops its drug pipeline.
Read more →QNRXQuoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
Quoin Pharmaceuticals Ltd. is set to announce its third quarter 2023 financial results on November 8, 2023. Following this, the company will conduct a conference call on November 9, 2023, at 8:30 am ET to discuss these results alongside a corporate update. Quoin specializes in developing therapeutic products aimed at treating rare and orphan diseases, indicating its commitment to addressing significant medical needs.
Read more →QNRX▲ +8%on this news
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
Quoin Pharmaceuticals has announced promising additional clinical data from its ongoing single-arm trial for QRX003, aimed at treating Netherton Syndrome. Out of six evaluable subjects, five showed significant improvement in pruritus and skin appearance after 12 weeks of treatment with QRX003. The preliminary safety data is encouraging, with no adverse events reported, which bodes well for the further development of the treatment. CEO Dr. Michael Myers expressed optimism about these results potentially marking a breakthrough in addressing an unmet medical need for patients with Netherton Syndrome.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome st
Quoin Pharmaceuticals announced positive clinical data from the first subject in its open-label study on Netherton Syndrome. The subject's skin condition showed complete clearance, and significant improvements were noted across other clinical endpoints. Both ongoing clinical studies are on track for patient enrollment completion by the end of August. The company reported a robust safety profile for its product QRX003, representing a noteworthy milestone for Quoin as they advance in their trials.
Read more →QNRXQuoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET
Quoin Pharmaceuticals Ltd. will release its second quarter 2023 financial results on August 2, 2023, followed by a conference call scheduled for August 3, 2023. The call aims to discuss the financial results and provide a corporate update. Quoin focuses on developing therapies for rare diseases and has four products in its pipeline, emphasizing its commitment to addressing unmet medical needs.
Read more →QNRXQuoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial
Quoin Pharmaceuticals has announced that its open label clinical trial for QRX003, targeting Netherton Syndrome, has reached 50% enrollment, having dosed five out of ten expected patients. The trial aims to evaluate the safety and efficacy of QRX003, a topical lotion, in patients receiving off-label systemic therapies. CEO Dr. Michael Myers expressed optimism about this milestone, highlighting the potential impact of the treatment on patient quality of life. Top-line data is anticipated in the latter half of 2023.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results First patient dosed in Quoin's single arm, open label clinical trial in Netherton Syndrome patients currently receiving o
Quoin Pharmaceuticals has provided a corporate update alongside its financial results for Q1 2023. The company has successfully dosed the first patient in its clinical trial for Netherton Syndrome and continues to recruit for both its studies. Following a successful public offering, Quoin expects its financial resources to last until the second half of 2024. However, the company also reported a significant net loss for the quarter, highlighting the financial challenges faced as it advances its clinical programs.
Read more →QNRXQuoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET
Quoin Pharmaceuticals Ltd. plans to release its first quarter 2023 financial results on May 8, 2023, followed by a conference call on May 9, 2023, at 8:30 am ET. The call will discuss the financial results and provide a corporate update to stakeholders and investors. Quoin specializes in developing treatments for rare and orphan diseases, with a pipeline including products targeting conditions such as Netherton Syndrome and Epidermolysis Bullosa.
Read more →QNRXQuoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial
Quoin Pharmaceuticals has dosed the first patient in its open-label clinical trial for QRX003, targeting Netherton Syndrome. This trial will assess the safety and efficacy of QRX003 in patients currently on off-label therapy. The study is being conducted alongside another trial under the company's open Investigational New Drug application. Quoin aims to report topline data from the study in the second half of 2023 and is optimistic about the potential of QRX003 to be the standard treatment for this rare condition.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter And Full Year 2022 Financial Results Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton
Quoin Pharmaceuticals has provided a corporate update and announced its fourth quarter and full year 2022 financial results. The company has initiated dosing for its first patient in a double-blinded clinical study evaluating QRX003 for Netherton Syndrome. Quoin also obtained FDA approval for a second trial to assess the safety and efficacy of QRX003, which aims to be conducted concurrently with the first study. Despite the promising developments, the company reported an increase in net loss and high operating expenses for the year.
Read more →QNRXQuoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET
Quoin Pharmaceuticals Ltd. has announced a conference call to discuss its financial results for the fourth quarter and year-end 2022, scheduled for March 9, 2023. The call will be accessible via a local and international dial-in number, along with a webcast available on their website. As a clinical stage company, Quoin focuses on developing therapies for rare and orphan diseases, highlighting its commitment to addressing unmet medical needs with its innovative pipeline.
Read more →QNRXQuoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering ASHBURN, Va.
Quoin Pharmaceuticals has announced the pricing of a $7.0 million public offering, which will involve the sale of 24,750,000,000 ordinary shares and pre-funded warrants. The offering is set to close on or about February 24, 2023, pending customary conditions. Proceeds from the sale are intended for general corporate purposes, and the company is also making adjustments to existing warrant exercise prices to potentially enhance investor interest and engagement.
Read more →QNRXQuoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome
Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing All Six Target Clinical Sites are on Track to be Fully Opened by Year End ASHBURN, Va., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results
Company completed a public offering for aggregate gross proceeds of $16.8 million Majority of clinical sites now open in clinical study to evaluate QRX003 for Netherton Syndrome Quoin announced plans to initiate second clinical trial to evaluate QRX003 in Netherton Syndrome pat
Read more →QNRXx200B; ​ ​ ​ ​ ​ ​ ​ ​ QUOIN PHARMACEUTICALS LTD. ​ Condensed Consolidated Financial Statements as of
242330247997803278032P3Y4846605670930335465079965266 QUOIN PHARMACEUTICALS LTD. Pag e Condensed Consolidated Financial Statements (Unaudited) Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 3 Consolidated Statements of Operations for the three and n
Read more →QNRXQuoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th
ASHBURN, Va., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today updated timing for its third quarter 2022 business update
Read more →QNRXQuoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th
ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its third quarter 2022 financial results will be repo
Read more →QNRXQuoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients
ASHBURN, Va., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces that it is initiating a second clinical trial in Netherton Syndrome patients. T
Read more →QNRXto the Company's Form 6-K furnished to the SEC on
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 27, 2022 Notice is hereby given that an Annual General Meeting (the "Annual Meeting") of Shareholders of Quoin Pharmaceuticals Ltd. (the "Company") will be held at The Logan, One Logan Square, Philadelphia
Read more →QNRXQuoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study
ASHBURN, Va., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has established a patient specific website: https://www.nethertonsyndromeclinicaltrials.c
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results
Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton Syndrome Expands number of commercial partnerships to eight, covering 60 countries Signs Research Agreement to develop a product for the treatment of scleroderma Closes $16.8 million public offeri
Read more →QNRXQuoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th
ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its second quarter 2022 financial results will be rep
Read more →QNRXQuoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering
ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the closing of its previously announced public offering of
Read more →QNRXQuoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering ASHBURN, Va.
Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering ASHBURN, Va., August 5, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orpha
Read more →QNRXQuoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe
ASHBURN, Va., July 28, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that it has received comprehensive and constructive Scientific A
Read more →QNRXQuoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements
ASHBURN, Va., July 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has entered into the License and Distribution Agreement and the Supply Agreement with Endo
Read more →QNRXQuoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study
ASHBURN, Va., July 06, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces that the first clinical site has now been fully opened for its clinical study to
Read more →QNRXQuoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China
ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced it has secured a license and distribution agreement with Hong Kong WinHeal
Read more →QNRXQuoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that the Company received a written notification (the "Notification Letter
Read more →QNRXQuoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University
ASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced it has signed a second, exclusive research agreement with the Queensland Un
Read more →QNRXQUOIN PHARMACEUTICALS LTD. Condensed Consolidated Financial Statements as of
QUOIN PHARMACEUTICALS LTD. QUOIN PHARMACEUTICALS LTD. Condensed Financial Statements (Unaudited) Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 3 Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 4 Consolidated Sta
Read more →QNRXQuoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome
ASHBURN, Va., April 25, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has received U.S. Food and Drug Administration (FDA) clearance to
Read more →QNRXQuoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome
ASHBURN, Va., March 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has submit
Read more →QNRXQuoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome
ASHBURN, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has submit
Read more →QNRXNOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 12, 2022 Notice is hereby given that an Annual General Meeting (the " Annual Meeting ") of Shareholders of Quoin Pharmaceuticals Ltd. (the " Company ")
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 12, 2022 Notice is hereby given that an Annual General Meeting (the "Annual Meeting") of Shareholders of Quoin Pharmaceuticals Ltd. (the "Company") will be held at The Logan, One Logan Square, Philadelphia,
Read more →QNRXQuoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome
ER-Kim Gains Exclusive Rights to Commercialize QRX003 to Six Additional Countries 60 Countries Now Covered by Partnership Agreements for QRX003 ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pha
Read more →QNRXQuoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome
Neopharm Gains Exclusive Rights to Commercialize QRX003 in Israel Sixth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specia
Read more →QNRXQuoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome
- ER-Kim Gains Exclusive Rights to Commercialize QRX003 Across Central & Eastern Europe - Fifth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Compan
Read more →QNRXNOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 28, 2022 Notice is hereby given that a Special General Meeting (the " Meeting ") of Shareholders of Quoin Pharmaceuticals Ltd. (the " Company ") wi
NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY Notice is hereby given that a Special General Meeting (the "Meeting") of Shareholders of Quoin Pharmaceuticals Ltd. (the "Company") will be held at the offices of the Company's Israeli legal counsel, S.
Read more →QNRXQuoin Pharmaceuticals Ltd. (the " Company ") Convening of a Special General Meeting of the Company The Company hereby gives notice of a Special General Meeting (the " Meeting ") that will take place on Monday, the 28th o
Quoin Pharmaceuticals Ltd. (the "Company") Convening of a Special General Meeting of the Company The Company hereby gives notice of a Special General Meeting (the "Meeting") that will take place on Monday, the 28th of February, 2022, at 4 p.m., at the offices of the Company's
Read more →QNRXQuoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome
- OrphanDC Gains Exclusive Rights to Commercialize QRX003 in Key Countries in Latin America - Fourth Distribution Partnership Established Since Going Public in October 2021 - Additional Territories in Discussion ASHBURN, Va., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuti
Read more →QNRXUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL On October 28, 2021, Quoin Pharmaceuticals, Ltd. (the "Company" or "Quoin Ltd."), formerly known as Cellect Biotechnology Ltd. ("Cellect"), completed the business combination with Quoin Pharmaceuticals, Inc., a Delaware corporat
Read more →QNRXFinancial statements as of
Financial statements as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020 (Unaudited) QUOIN PHARMACEUTICALS, INC. Contents Page Financial Statements (Unaudited) Condensed Balance Sheets as of September 30, 2021 and December 31, 2020 2
Read more →QNRXQuoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome
ASHBURN, Va., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered
Read more →QNRXQuoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoin’s Lead Asset, QRX003
ASHBURN, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, and Genpharm Services, a regional rare disease and specialty pharmaceutical company, today
Read more →QNRXQuoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003
AFT Gains Exclusive Rights to Commercialize QRX003 in Australia and New Zealand ASHBURN, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today ann
Read more →QNRXQuoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial Officer
ASHBURN, Va., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has appointed Gordon Dunn as Quoin’s Chief Financial Officer, effe
Read more →QNRXQuoin Pharmaceuticals Announces Signing of Exclusive License from Queensland University of Technology, Australia
ASHBURN, Va., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed an agreement with Queensland University of Technology,
Read more →QNRXQuoin Pharmaceuticals Completes Merger and Will Commence Trading on Nasdaq Capital Market under Ticker Symbol "QNRX" Concomitant Investment from Altium Capital Secured Ashburn, VA, October 28 , 2021 -- Quoin Pharmaceutic
Pharmaceuticals Completes Merger and Will Commence Trading on Nasdaq Capital Market under Ticker Symbol "QNRX" Investment from Altium Capital Secured VA, October 28 , 2021 -- Quoin Pharmaceuticals, Ltd., (NASDAQ: QNRX) (the "Company"), a specialty pharmaceutical company focuse
Read more →QNRXCellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals Tel Aviv
Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals Tel Aviv - October 15, 2021 - Cellect Biotechnology Ltd. (NASDAQ: "APOP") (the "Company"), announced today the record date and distribution
Read more →QNRXCellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals Tel Aviv
Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals Aviv - September 27, 2021 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with private
Read more →QNRXAMENDMENT AGREEMENT AMENDMENT AGREEMENT (this Agreement ), dated as of September [ ], 2021 by and among Quoin Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 42127 Pleasant Forest Ct, Ashburn,
AMENDMENT AGREEMENT (this "Agreement"), dated as of September [ ], 2021 by and among Quoin Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 42127 Pleasant Forest Ct, Ashburn, VA 20148 ("Quoin"), Cellect Biotechnology Ltd., an Israeli company, with he
Read more →QNRXCellect Biotechnology Announces the ApoGraft TM Bone Marrow Transplantation of First Patient in U.S. Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX Tel Aviv
Cellect Biotechnology Announces the ApoGraftTM Bone Marrow Transplantation of First Patient in U.S. Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX Tel Aviv - September 2, 2021 - Reflecting continued clinical progress,
Read more →QNRXCellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results Strategic Merger Transaction Remains on Track to Close During the 2021 Third Quarter Tel Aviv, Israel
Biotechnology Reports Second Quarter 2021 Financial and Operating Results Merger Transaction Remains on Track to Close During the 2021 Third Quarter Aviv, Israel August 24, 2021 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables th
Read more →QNRXThe Securities and Exchange Commission Declared Cellect Biotechnology's Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals Special G
The Securities and Exchange Commission Declared Cellect Biotechnology's Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals Special General Meeting of Shareholders Scheduled for September 1
Read more →QNRXCellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals Transaction Expected to Close in the 2021 Third Quarter Tel Aviv, Israel
Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals Transaction Expected to Close in the 2021 Third Tel Aviv, Israel June 16, 2021 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of in
Read more →QNRXCellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial Results Support Ongoing Clinical Development of ApoGraft in U.S. Tel Aviv, Israel
Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial Results Support Ongoing Clinical Development of ApoGraft in U.S. Tel Aviv, Israel April 19, 2021 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the fun
Read more →QNRXCellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results Tel Aviv, Israel
Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results Tel Aviv, Israel March 28, 2021 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today repor
Read more →QNRXCellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger Up to $25.25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger Cellect sh
Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger to $25.25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the shareholders to retain approximately 25% of the combined Company pre-funding Aviv, Is
Read more →QNRXCellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021 Promising Progress on Clinical Development Progress, Collaborations and Par
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021 Promising Progress on Clinical Development Progress, Collaborations and Partnering Mutually Ended Discussion on Medical Cannabis C
Read more →QNRXCellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology Tel Aviv, Israel
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology Tel Aviv, Israel October 29, 2020 - Adding to a growing roster of partners, Cellect Biotechnology Lt
Read more →QNRXCellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft Tel Aviv, Israel
Cellect Biotechnology Initiates U.S. Clinical Tel Aviv, Israel October 22, 2020 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of cells facilitating safer and more efficacious cell and gene therapies,
Read more →QNRXCELLECT BIOTECHNOLOGY LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting (the "Annual Meeting") of Shareholders of Cellect Biotechnology Ltd. (the "Company") will
OF ANNUAL GENERAL MEETING OF SHAREHOLDERS is hereby given that an Annual General Meeting (the "Annual Meeting") of Shareholders of Cellect Biotechnology Ltd. (the "Company") will be held at the offices of the Company's attorney - Doron, Tikotzky, Kantor, Gutman Nass, Amit Gros
Read more →QNRXCellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa Management to Highlight Progress in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business Collaborations Tel Aviv,
Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa Management to Highlight Progress in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business Collaborations Tel Aviv, Israel September 21, 2020 - Cellect Biotechnology Ltd.
Read more →QNRXCELLECT BIOTHECHNOLOGY LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2020 NIS IN THOUSANDS UNAUDITED INDEX Page Consolidated Balance Sheets F - 2 Consolidated Statements of Comprehensive Loss F-3 Statemen
CELLECT BIOTHECHNOLOGY LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Balance Sheets F - 2 Consolidated Statements of Comprehensive Loss F-3 Statements of Changes in Equity F - 4 Consolidated Statements of Cash Flows F - 5 - F-6 Notes to Interim Consolidated
Read more →QNRXEuropean Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation Strengthened Intellectual Property Portfolio Enables Acceleration of Business Development Activities Tel Aviv, Israel
Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation Intellectual Property Portfolio Enables Acceleration of Business Development Activities Aviv, Israel August 6, 2020 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative techn
Read more →QNRXCellect Biotechnology Reports First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Adjust ed Operations Du e to COVID- 19 Tel Aviv, Israel
Biotechnology Reports First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Tel Aviv, Israel May 21, 2020 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selecti
Read more →QNRXCellect Biotechnology's ApoGraft to Empower Cellular Treatment of COVID-19 Related Pulmonary Diseases Signs Development Agreement with International Consortium; Royalties Will be Based on Commercialization of Future Prod
Cellect Biotechnology's ApoGraft to Empower Cellular Treatment of COVID-19 Related Pulmonary Diseases Signs Development Agreement with International Consortium; Royalties Will be Based on Commercialization of Future Products Clinical Results in GvHD Studies May be Beneficia
Read more →QNRXCellect Biotechnology Announces Positive Data Demonstrating Robust Engraftment Using ApoGraft Was Featured in Bone Marrow Transplantation; Primary Data Points Were Submitted to the FDA During Investigational New Drug App
Biotechnology Announces Positive Data Demonstrating Robust Engraftment Using ApoGraft Was Featured in Bone Marrow Transplantation; Primary Data Points Were Submitted to the FDA During Investigational New Drug Approval Process Aviv, Israel May 11, 2020 - Cellect Biotechnology Lt
Read more →QNRXCellect Biotechnology Continues to Achieve Milestones; Receives New Patent Allowance in Canada Tel Aviv, Israel
Cellect Biotechnology Continues to Achieve Milestones; Receives New Patent Allowance in Canada Tel Aviv, Israel - April 27, 2020 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, received
Read more →QNRXCELLECT BIOTECHNOLOGY LTD. NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that a Special General Meeting (the "Special Meeting") of Shareholders of Cellect Biotechnology Ltd. (the "Company") wil
OF SPECIAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that a Special General Meeting (the "Special Meeting") of Shareholders of Cellect Biotechnology Ltd. (the "Company") will be held at the offices of the Company's legal counsel - Doron, Tikotzky, Kantor, Gutman,
Read more →QNRXCellect Biotechnology Reports Fourth Quarter and Full Year 2019 Results Achieved Primary Investigational New Drug (IND) Approval in the U.S.; Positioned to Commence Patient Enrollment Maintained Clinical Progress in Isra
Biotechnology Reports Fourth Quarter and Full Year 2019 Results Primary Investigational New Drug (IND) Approval in the U.S.; Positioned to Commence Patient Enrollment Clinical Progress in Israel and Nearing Completion of Phase 1/2 Trial Commercial Agreement with Canndoc Antici
Read more →QNRXCellect Biotechnology Receives New Patent Allowance in China
Cellect Biotechnology Receives New Patent Allowance in China Israel, April 2, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, received an official communication from the C
Read more →QNRXCellect Biotechnology and Canndoc Ltd. to enter into Strategic Pharma Grade Cannabis Commercial Deal for Reduction in Opioid Usage Pharma Grade Cannabis products and Expertise combined with clinical development capabilit
Cellect Biotechnology and Canndoc Ltd. to enter into Strategic Pharma Grade Cannabis Commercial Deal for Reduction in Opioid Usage Pharma Grade Cannabis products and Expertise combined with clinical development capabilities enable Cellect to Become a leading Player Addressing
Read more →QNRXOF SPECIAL GENERAL MEETING OF SHAREHOLDERS
OF SPECIAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that a Special General Meeting (the "Special Meeting") of Shareholders of Cellect Biotechnology Ltd. (the "Company") will be held at the offices of the Company's legal counsel - Doron, Tikotzky, Kantor, Gutman,
Read more →QNRXCELLECT BIOTECHNOLOGY LTD. PRICES $3M
BIOTECHNOLOGY LTD. PRICES $3M REGISTERED DIRECT OFFERING OF AMERICAN DEPOSITARY SHARES AVIV, Israel, Jan. 8, 2020 / -- Cellect Biotechnology Ltd. (Nasdaq: APOP) ("Cellect" or the "Company"), a developer of innovative technology which enables the functional selection of stem c
Read more →QNRXBiotechnology Strengthens IP Portfolio; Receives "Intention to Grant" Patents from European and Israeli Patent Offices
Biotechnology Strengthens IP Portfolio; Receives "Intention to Grant" Patents from European and Israeli Patent Offices IP Protection Creates Barriers to Entry and Supports the Company's Business Opportunities Aviv, Israel - January 7, 2020 - Cellect Biotechnology Ltd. (Nasdaq:
Read more →QNRXReceives Approval for U.S.
Cellect Biotechnology Receives Approval for U.S. Clinical Trial Clinical Trial to Assess the ApoGraft Technology for Haploidentical Bone Marrow Transplantations to be Conducted at Washington University School of Medicine (St. Louis) Tel Aviv, Israel - December 23, 2019 - Ce
Read more →QNRXCellect Biotechnology Reports Third Quarter 2019 Financial and Operating Results Tel Aviv, Israel
Cellect Biotechnology Reports Third Quarter 2019 Financial and Operating Results Tel Aviv, Israel November 19, 2019 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, today reported financi
Read more →QNRXRegains Compliance with Nasdaq Minimum Bid Price Requirement
Cellect Biotechnology Regains Compliance with Nasdaq Minimum Bid Price Requirement Tel Aviv, Israel November 7, 2019 /Globe Newswire/ - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of innovative technology which enables the functional selection of stem cells, announ
Read more →QNRXCELLECT BIOTHECHNOLOGY LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2019 NIS IN THOUSANDS UNAUDITED INDEX Page Consolidated Balance Sheets F - 2 Consolidated Statements of Comprehensive Loss F-3 Statemen
CELLECT BIOTHECHNOLOGY LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Balance Sheets F - 2 Consolidated Statements of Comprehensive Loss F-3 Statements of Changes in Equity F - 4 Consolidated Statements of Cash Flows F - 5 - F-6 Notes to Interim Consolidated
Read more →QNRXCellect Biotechnology Announces Positive
Cellect Biotechnology Announces Positive Outcome from Safety Review Committee; Successfully Transplants 9th Clinical Trial Patient progress as Washington University's Scientific Review Committee Approved the Company's First U.S. Study TEL AVIV, Israel - August 12, 2019 - Fol
Read more →QNRXBiotechnology and Washington University (WU)
Biotechnology and Washington University (WU) Accelerated Clinical Trial Agreement Achieves First Significant Milestone with Successful Execution of Technology Transfer Significant Milestones, Including Submission of the Investigational New Drug (IND) Application Which is Exp
Read more →QNRXGENERAL MEETING OF SHAREHOLDERS
CELLECT BIOTECHNOLOGY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting (the "Annual Meeting") of Shareholders of Cellect Biotechnology Ltd. (the "Company") will be held at the offices of the Company's legal counsel - Doron, Tikotzky, Kanto
Read more →QNRXBiotechnology Reports First Quarter 2019 Financial and Operating Results
Biotechnology Reports First Quarter 2019 Financial and Operating Results Aviv, Israel May 21, 2019 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating re
Read more →QNRXCellect Biotechnology to Explore Strategic Alternatives to Maximize Shareholder Value Tel Aviv, Israel
Cellect Biotechnology to Explore Strategic Alternatives to Maximize Shareholder Value Tel Aviv, Israel May 16, 2019 /Globe Newswire/ - Following a review of its business, including the status of its clinical and development programs, resources and capabilities, Cellect Biotec
Read more →QNRXEnabling regenerative medicine May 2019
Enabling regenerative medicine May 2019 This presentation includes statements that are, or may be deemed, forward - looking statements . " In some cases, these forward - looking statements can be identified by the use of forward - looking terminology, including the terms "believ
Read more →QNRXAnnounces Positive Phase I/II Mid-Study Results of its ApoGraft Technology
Announces Positive Phase I/II Mid-Study Results of its ApoGraft Technology Completion of First half of ApoGraft Phase I/II Clinical Trial Shows 100% Engraftment and No Related Adverse Effects Aviv, Israel March 27, 2019 - Further validating its ApoGraft technology, Cellect Biot
Read more →QNRXBiotechnology Reports Fourth Quarter and Full Year 2018 Results and Recent Corporate Progress
Biotechnology Reports Fourth Quarter and Full Year 2018 Results and Recent Corporate Progress Execution Positions the Company for Expedited Progress in 2019 Aviv, Israel March 18, 2019 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production tec
Read more →QNRXCellect Announces Positive Results from Cell2in Collaboration Showing Significant Improvement in Expansion Rate and Function of Stem Cells Results and Validation of ApoGraft technology from a variety of sources could lea
Announces Positive Results from Cell2in Collaboration Showing Significant Improvement in Expansion Rate and Function of Stem and Validation of ApoGraft technology from a variety of sources could lead to a more cost-effective solution for the cell Aviv, Israel March 11, 2019 -
Read more →QNRXCellect Announces Closing of $6.5 Million Underwritten Public Offering Tel Aviv, Israel
Cellect Announces Closing of $6.5 Million Underwritten Public Offering Tel Aviv, Israel - February 13, 2019 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced the closing of its previously announced $6.5 millio
Read more →QNRXAnnounces Pricing of $6.5 Million Public Offering
Announces Pricing of $6.5 Million Public Offering Aviv, Israel, February 8, 2019 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced the pricing of an underwritten public offering of 1,889,000 un
Read more →QNRXCellect Begins Collaboration with Washington
Cellect Begins Collaboration with Washington University in preparation for First U.S. Clinical Trial Using Cellect's ApoGraft for Bone Marrow Transplantations The Collaboration will be led by Renowned Cell and Gene Therapy Experts Dr. John DiPersio and Dr. Mark Schroeder wit
Read more →QNRXof Manufacturing of Clinical Grade FasL Enables Cellect to Expedite
of Manufacturing of Clinical Grade FasL Enables Cellect to Expedite U.S. Clinical Programs into Multiple Studies Collaborations with Cell and Gene Therapy Companies Aviv, Israel - January 28, 2019 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell p
Read more →QNRXThe risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your inve
Throughout this update, unless otherwise designated, the terms "we", "us", "our", "Cellect", "the Company" and "our Company" refer to Cellect Biotechnology Ltd. and its wholly-owned subsidiaries. References to "ordinary shares", "ADSs", "warrants" and "share capital" refer to
Read more →QNRXBiotechnology Reports Clinical and Regulatory Milestone Targets
Biotechnology Reports Clinical and Regulatory Milestone Targets FDA Hiring Decision Highlights Growing Importance of Cell and Gene Therapy Companies Aviv, Israel - January 23, 2019 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a novel regenerative and cell therapy company with
Read more →QNRXapproves Cellect's grant application
the agreement signed with South Korean Cell2in approves Cellect's grant application Korea-Israel Industrial R&D Foundation (KORIL-RDF) approves grant for the collaboration between Cellect and Cell2in, providing financing for the joint project Shai Yarkoni, Cellect CEO commen
Read more →QNRXBiotechnology Provides Corporate Update and Reports Third Quarter 2018 Financial Results
Biotechnology Provides Corporate Update and Reports Third Quarter 2018 Financial Results Tel Aviv, Israel November 13, 2018 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, today provided
Read more →QNRXCellect Receives Multiple Patent Grants Following US, EU, Russia and South Korean approval: Cellect Technology Patent has now also been approved in Japan & Australia PATENT COVERS FIRST-IN-KIND DEVICES USING CELLECT'S FL
Cellect Receives Multiple Patent Grants Following US, EU, Russia and South Korean Cellect Technology Patent has now also been approved in Japan & Australia PATENT COVERS FIRST-IN-KIND DEVICES USING CELLECT'S FLAGSHIP TECHNOLOGY, THE APOGRAFT WHICH IS INTENDED TO REPLACE HIGH
Read more →QNRXAnnounces a Major Technological Breakthrough for
Announces a Major Technological Breakthrough for Industrialization of Apotainer Stem Cell Product Line first in kind (patent pending) technology of FasL-magnetic beads significantly improve the stem cells selection process beads are used within Cellect's ApoTainer and designe
Read more →QNRXPositive Results of Orthopedic Treatment With The Use Of ApoGraft Enriched Stem Cells Derived from Fat Tissues Study shows significant improvement in orthopedic healing process Dr. Shai Yarkoni, Company CEO : "Cellect sh
Orthopedic Treatment With The Use Of ApoGraft Derived from Fat Tissues Study shows significant improvement in orthopedic healing process Dr. Shai Yarkoni, Company CEO : "Cellect shows promise of ApoGraft technology in use for orthopedic indications treated by fat-derived ste
Read more →QNRXAnnounces Positive Clinical Results
Announces Positive Clinical Results AVIV, Israel, October 15th, 2018 -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today further data from a Phase I/II study of its ApoGraft technology. With half of the patient
Read more →QNRXCellect Receives Notice of Allowance for Stem Cell Selection Technology Patent in Korea - In Korea, Cellect recently signed collaboration agreement with Cell2in to improve stem cell selection and expansion - Covers use o
Receives Notice of Allowance for Stem Cell Selection Technology Patent in Korea AVIV, Israel, August 20, 2018 -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today it has received a Notice of Allowance from the Kor
Read more →QNRXCellect and Cell2in Launch Collaboration to Significantly Improve Stem Cell Selection and Expansion - Aim is to combine the benefits of mutual technologies to enable higher quality cells at a lower cost - Collaboration i
and Cell2in Launch Collaboration to Significantly Improve Stem Cell Selection and Expansion AVIV, Israel, August 13, 2018 -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today that it has signed a collaboration agr
Read more →QNRXCELLECT BIOTHECHNOLOGY LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2018 NIS IN THOUSANDS UNAUDITED INDEX Page Consolidated Balance Sheets F- 2 Consolidated Statements of Comprehensive Loss F-3 Statement
CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Balance Sheets F- 2 Consolidated Statements of Comprehensive Loss F-3 Statements of Changes in Equity F- 4 Consolidated Statements of Cash Flows F- 5 - F-6 Notes to Interim Consolidated Financial Statements F- 7 - F - 13 - -
Read more →QNRXCellect Granted Key European Patent for its Stem Cell Selection Technology - Covers use of the ApoTainer device, as well as methods employing the device in stem cell selection for conditions including GvHD - Expected to
Granted Key European Patent for its Stem Cell Selection Technology TEL AVIV, Israel, August 7, 2018 -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today the European Patent Office has granted the company a patent
Read more →QNRXOF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS is hereby given that an Extraordinary General Meeting of Shareholders of Cellect Biotechnology Ltd. (the "Company") will be held at the offices of the Company's legal counsel - Doron, Tikotzky, Kantor, Gutman & Amit Gross, at B.
Read more →QNRXSigned Strategic Agreement
Signed Strategic Agreement Swiss Biotech Center (SBC) secures exclusive clinical production capacity of the main active ingredient in Cellect's ApoGraft Shai Yarkoni, Cellect CEO commented: partnership with SBC is a major achievement for Cellect in securing the production an
Read more →QNRXsigns Collaboration Agreement
signs Collaboration Agreement will combine their proprietary technologies with the goal of enhancement of growth and functionality of stem cells Aviv, Israel - July 5, 2018 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, an
Read more →QNRXOF ANNUAL GENERAL MEETING OF SHAREHOLDERS
OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting (the "Annual Meeting") of Shareholders of Cellect Biotechnology Ltd. (the "Company") will be held at the offices of the Company's legal counsel - Doron, Tikotzky, Kantor, Gutman & A
Read more →QNRXBiotechnology Ltd.
Biotechnology Ltd. Provides Corporate Update and Reports First Quarter 2018 Financial Results Aviv, Israel May 17, 2018 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, today provided a co
Read more →QNRXFormer GE Healthcare executive to join Cellect as Chief Business Officer. Andrew Sabatier, formerly the US Sales and Market Development Leader for GE Cell Therapy, will be heading up the commercialization of Cellect Apog
Former GE Healthcare executive to join Cellect as Chief Business Officer. Andrew Sabatier, formerly the US Sales and Market Development Leader for GE Cell Therapy, will be heading up the commercialization of Cellect Apograft technology, as well as new business development. D
Read more →QNRXmajor milestone for enabling stem cells production
major milestone for enabling stem cells production completes POC testing for first ever scalable production of ApoTainer ApoTainer built to replace complex laboratory procedures for stem cell extraction at a fraction of the time and cost Shai Yarkoni, Cellect CEO commented: b
Read more →QNRXCellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results Tel Aviv, Israel
Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results Tel Aviv, Israel March 19, 2018 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem c
Read more →QNRXCellect Biotechnology Announces $4 Million
Cellect Biotechnology Announces $4 Million Registered Direct Offering Tel Aviv, Israel - January 29, 2018 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of stem cells selection technology, announced that it has entered into securities purchase agreements with certai
Read more →QNRXCellect Announces Opening of a Second Clinical Trial Site and Approval from Safety Board (DSMB) for Dose Escalation Cellect signs agreement with Hadassah Medical Center to conduct ApoGraft Clinical Trial Dr. Shai Yarkoni
Second Clinical Trial Site Safety Board (DSMB) for Dose Escalation agreement with Hadassah Medical Center to conduct Cellect CEO commented: rapidly moving towards commercialization of our technology and its mass usage in regenerative medicine." - January 16th, 2018 - Cellect
Read more →QNRXGroup of Patients in Clinical Trial with Cellect's ApoGraft Stem Cell Transplant Follow up Results
Group of Patients in Clinical Trial with Cellect's ApoGraft Stem Cell Transplant Follow up Results Zero Related Adverse Events Yarkoni, Cellect CEO commented: interim results further support that we are closer than ever to a world where stem cells are used to replace sick orga
Read more →QNRXBiotechnology Ltd Provides Corporate Update and Reports Third Quarter 2017 Financial Results
Biotechnology Ltd Provides Corporate Update and Reports Third Quarter 2017 Financial Results Aviv, Israel November 22, 2017 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, today provided a
Read more →QNRXCELLECT BIOTECHNOLOGY LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders and American Depositary Share (" ADS ") holders of Cellect B
OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders and American Depositary Share ("ADS") holders of Cellect Biotechnology Ltd. (the "Company") will be held at the offices of the Company's legal counsel,
Read more →QNRXCellect announces a major breakthrough of its ApoGraft technology Reporting today positive results from a 20 patients trial with Tel-Aviv Ichilov Medical Center ApoGraft significantly improved stem cells derived from fat
announces a major breakthrough of its ApoGraft technology today positive results from a 20 patients trial Tel-Aviv Ichilov Medical Center significantly improved stem cells derived from fat tissues Shai Yarkoni: "This breakthrough finding is increasing our addressable market
Read more →QNRXCellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development Officer Tel Aviv, Israel
Cellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development Officer Tel Aviv, Israel - October 19, 2017 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of stem cells selection technology, announced today that it has nominated Dr. Ronit Bakimer-Kleiner as Chief De
Read more →QNRXCellect's ApoGraft for Acute GvHD and Chronic GvHD
Grants Orphan Drug Status Cellect's ApoGraft for Acute GvHD and Chronic GvHD aims to solve Bone Marrow Transplantation (BMT) other transplant rejection associated diseases CEO, Dr. Shai Yarkoni commented "We may provide the answer to a great unmet clinical need causing severe
Read more →QNRXCELLECT BIOTHECHNOLOGY LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 NIS IN THOUSANDS UNAUDITED INDEX Page Consolidated Balance Sheets F-2 Consolidated Statements of Comprehensive Loss F-3 Statements
CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Balance Sheets F-2 Consolidated Statements of Comprehensive Loss F-3 Statements of Changes in Equity F-4 Consolidated Statements of Cash Flows F-5 - F-6 Notes to Interim Consolidated Financial Statements F-7 - F-11 - - - - -
Read more →QNRXUnofficial Translation into English from Hebrew Cellect Biotechnology Ltd. (the "Company") Re: Update on the Announcement on Moving to Exclusive Trading on the NASDAQ Cellect Biotechnology Ltd., No. 52-003648-4 (the "Com
Unofficial Translation into English from Cellect Biotechnology Ltd. Cellect Biotechnology Ltd., No. 52-003648-4 (the "Company") is pleased to announce that on September 5, 2017, the Company is moving to exclusive trading on the NASDAQ and that shareholders who are interested
Read more →QNRXFollowing the US, Cellect Receives Russian Patent Covering any Device and Method Using Cellect's Flagship Technology - the ApoGraft PATENT COVERS FIRST-IN-KIND DEVICES FOR SIMPLE AND ROBUST STEM CELL SELECTION REPLACING
Cellect Receives Russian Patent Covering any Device and Method Using Cellect's Flagship Technology - the ApoGraft PATENT COVERS FIRST-IN-KIND DEVICES FOR SIMPLE AND ROBUST STEM CELL SELECTION REPLACING HIGH-COST AND COMPLEX PROCESSES USED TODAY Dr. Shai Yarkoni, CEO, commen
Read more →QNRXCellect Receives Notice of Allowance from the US Patent & Trademark Office Patent Covers Any Device Using Cellect's Flagship Technology - the ApoGraft PROVIDES COMMERCIAL PROTECTION FOR FIRST-IN-KIND DEVICES FOR SINGLE-S
Cellect Receives Notice of Allowance from the US Patent & Trademark Office Any Device Using Cellect's Flagship Technology - the ApoGraft PROVIDES COMMERCIAL PROTECTION FOR FIRST-IN-KIND FOR SINGLE-STEP STEM CELL SELECTION REPLACING HIGH-COST AND COMPLEX PROCEESES USED TODAY
Read more →QNRXCellect is moving to trade exclusively on the NASDAQ Cellect shareholders can now exchange Israeli-traded ordinary shares for NASDAQ American Depositary Shares, each representing 20 ordinary shares Cellect Chairman, Nuri
is moving to trade exclusively on the NASDAQ Cellect shareholders can now exchange Israeli-traded ordinary shares for NASDAQ American Depositary Shares, each representing 20 ordinary shares Cellect Chairman, Nuriel Chirich Kasbian commented: "Our shareholders will be able to con
Read more →QNRXCellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2017 Financial Results Tel Aviv, Israel
Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2017 Financial Results Tel Aviv, Israel May 29, 2017 - Cellect Biotechnology Ltd. (NASDAQ: "APOP", TASE: "APOP"), a developer of innovative technology which enables the functional selection of stem
Read more →QNRXCellect Gets Green Light from FDA For ApoGraft IND submission in the U.S. Cellect's CEO, Dr. Shai Yarkoni commented "The U.S. market is key for our planned commercial expansion and this will allow us to work tightly with
Cellect Gets Green Light from FDA For ApoGraft IND submission in the U.S. Cellect's CEO, Dr. Shai Yarkoni commented "The U.S. market is key for our planned commercial expansion and this will allow us to work tightly with the top U.S. institutes and global pharma companies on
Read more →QNRXGENERAL MEETING OF SHAREHOLDERS AND SERIES-1 STOCK OPTIONS
CELLECT BIOTECHNOLOGY NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS AND SERIES-1 STOCK OPTIONS Notice is hereby given that an Extraordinary General Meeting (the "Extraordinary General Meeting") of Shareholders and holders of Series-1 Stock Options (the "Warrants")
Read more →QNRXCellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company's Technology in Multiple Indications Patent to provide coverage in both U.S. and EU Method of treatment patent provi
Cellect Receives Notice of Intention from European Patent Office for Patent Protecting Company's Technology in Multiple Indications Patent to provide coverage in both U.S. Method of treatment patent provide protection in diabetes, inflammatory bowel disease, graft-versus-hos
Read more →QNRXSuccessful First Cancer Patient Stem
Successful First Cancer Patient Stem technology, ApoGraft , aims to become a game changer stem cells transplantations for cancer treatments Company gets green light from DSMB Board for enrolling additional 2 cancer patients for ApoGraft transplantation treatments Tel Aviv, I
Read more →QNRXEnabling Stem Cells Corporate Presentation 2017 This presentation includes statements that are, or may be deemed, forward - looking statements . " In some cases, these forward - looking statements can be identified by th
Enabling Stem Cells Corporate Presentation 2017 This presentation includes statements that are, or may be deemed, forward - looking statements . " In some cases, these forward - looking statements can be identified by the use of forward - looking terminology, including the terms
Read more →QNRXCellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results Tel Aviv, Israel
Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results Tel Aviv, Israel March 23, 2017 - Cellect Biotechnology Ltd. (NASDAQ: "APOP", TASE: "APOP"), a developer of innovative technology which enables the functional sele
Read more →QNRXFormer Head, Clinical Development and
Michael Berelowitz MD., Former Head, Clinical Development and Pfizer Specialty Care Business Unit Cellect's Board of Directors Tel Aviv, Israel - March 2nd, 2017 - Cellect Biotechnology Ltd. (Nasdaq: APOP, TASE: APOP), a developer of stem cells isolation technology, today an
Read more →QNRXCellect Announces Positive Clinical Trial Results ApoGraft TM , Cellect's flagship technology, validated as safe, robust and reproducible process for clinical use after a 104 donor test base Cellect CEO: "In plain words,
Cellect Announces Positive Clinical Trial ApoGraft TM, Cellect's flagship technology, validated as safe, robust and reproducible process for clinical use after a 104 donor test base Cellect CEO: "In plain words, these positive results bring us one step closer to making stem c
Read more →QNRXCellect Receives Patent Notice of Allowance from US Patent & Trademark Office Protecting Company's Technology in Multiple Key Indications Method of treatment patent provides important protection in type I diabetes, infla
Cellect Receives Patent Notice of Allowance from US Patent & Trademark Office Protecting Company's Technology in Multiple Key Indications Method of treatment patent provides important protection in type I diabetes, inflammatory bowel disease, graft versus host disease and tra
Read more →QNRXCellect Biotechnology Ltd Provides Corporate Update and Reports Third Quarter 2016 Financial Results Tel Aviv, Israel
Cellect Biotechnology Ltd Provides Corporate Update and Reports Third Quarter 2016 Financial Results Tel Aviv, Israel November 28, 2016 - Cellect Biotechnology Ltd. (NASDAQ: "APOP", TASE: "APOP"), a developer of innovative technology which enables the functional selection of
Read more →QNRXCellect Biotechnology Ltd. (the "Company")
Cellect Biotechnology Ltd. To To The Israel Securities Authority The Tel Aviv Stock Exchange 22 Kanfei Nesharim St. 3 Ahuzat Bayit St. Jerusalem, 95464 Tel Aviv, 65202 Via MAGNA Via MAGNA To Whom It May Concern: Re: Submission of Request for Patent in the Field of Stem Cell S
Read more →QNRXReceives Israeli Ministry of Health Approval to Initiate Phase I/II
Receives Israeli Ministry of Health Approval to Initiate Phase I/II Clinical Trial in Leukemia Patients innovative cell selection product may dramatically reduce bone marrow transplantation risks enrollment expected to begin in the next few weeks Tel Aviv, Israel - September
Read more →QNRXCellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2016 Financial Results Raised Gross Proceeds of $8.4 Million through Pricing of July U.S. Initial Public Offering Tel Aviv, Israel
Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2016 Financial Results Raised Gross Proceeds of $8.4 Million through Pricing of July U.S. Initial Public Offering Tel Aviv, Israel August 31, 2016 - Cellect Biotechnology Ltd. (NASDAQ: "APOP", TAS
Read more →QNRXCellect Biotechnology Ltd. to Present at 18 th Annual Rodman & Renshaw Global Investment Conference on
Cellect Biotechnology Ltd. to Present at 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016 Kfar Saba, Israel - August 25, 2016 - Cellect Biotechnology Ltd. (Nasdaq: "APOP", TASE: "APOP"), a developer of innovative technology which enables the fun
Read more →QNRXCellect Biotechnology Ltd.
Cellect Biotechnology Ltd. To: To: Israel Securities Authority ( ISA ) Tel-Aviv Stock Exchange Ltd. ( TASE ) Via Magna Via Magna www.isa.co.il www.tase.co.il In accordance with the decision of the Company's Board of Directors from August 10, 2016, the Company wishes to hereby
Read more →QNRXCellect Biotechnology Ltd. ("The Company")
Cellect Biotechnology Ltd. To: To: Israel Securities Authority (ISA) Tel-Aviv Stock Exchange Ltd. ( TASE ) Via Magna Via Magna www.isa.co.il www.tase.co.il In accordance with the decision of the Company's Board of Directors from August 10, 2016, the Company wishes to hereby su
Read more →QNRXCellect Biotechnology Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing Kfar Saba, Israel
Biotechnology Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing Kfar Saba, Israel, July 29, 2016 - Cellect Biotechnology Ltd. (NASDAQ: APOP, APOPW; TASE: CLBD), a developer of innovative technology which enables the functional selection of stem cells, t
Read more →Competitive Position
How QNRX ranks across every disease it competes inCompetitive Position is a premium feature
See how QNRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial